Cosmos Health Inc. Stock Price, News & Analysis

Cosmos Holdings (NASDAQ:COSM) has announced the launch of Mediterranation, a premium line of nutritional supplements under its Sky Premium Life brand. This line utilizes organic herbs and plant extracts sourced from Greece and the Mediterranean, featuring ingredients known for their health benefits, including polyphenols with antioxidant properties. CEO Greg Siokas highlighted the anticipated demand for these high-quality supplements and the company's growth strategy to expand into new global markets. Manufacturing adheres to strict pharmaceutical standards, ensuring quality.

Cosmos Holdings (NASDAQ:COSM) announced the launch of its Sky Premium Life products on Amazon Singapore, achieving the rollout ahead of schedule, with plans for 15 SKUs initially and 85 SKUs by year-end. This move comes as the Singapore e-commerce market is expected to grow from $5.9 billion in 2021 to $10.7 billion by 2025, driven by increasing online shopping preferences.

CEO Greg Siokas emphasized the significance of this launch in expanding their global market strategy amidst rising demand for nutraceuticals.

Cosmos Holdings (NASDAQ:COSM) has launched Brainlit, a new brain health supplement under its luxury line, Sky Premium Life. This product aims to address rising brain-related conditions like Alzheimer's, affecting over 55 million globally. The brain health supplement market is projected to grow from $7.7 billion in 2020 to $19.7 billion by 2030, driven by an aging population and increased demand for effective treatments. The formula includes key ingredients like ginkgo biloba, glutamine, and L-tyrosine, contributing to enhanced cognitive function.

Cosmos Holdings (Nasdaq: COSM) announces the launch of Prostatium, a proprietary supplement aimed at enhancing prostate health and preventing symptoms of Benign Prostate Hyperplasia (BPH). With about 30 million men affected worldwide, Prostatium includes proven ingredients like Saw Palmetto and Lycopene, manufactured under stringent standards. The company aims to expand its product reach across Europe and North America while tapping into the growing demand for high-quality nutraceuticals. CEO Greg Siokas highlighted the importance of this unique formulation developed by their R&D team.

Cosmos Holdings (NASDAQ:COSM) announced its participation in the Virtual Growth Conference hosted by Maxim Group LLC on March 28-30, 2022, from 9:00 a.m. to 5:00 p.m. ET. Investors can access the Company's pre-recorded presentation over these three days. The event will cover various sectors, including Biotech, Clean Energy, and Healthcare, featuring presentations, fireside chats, and discussions with CEOs. Cosmos Holdings is an international pharmaceutical company specializing in nutraceuticals and distributing pharmaceuticals across Europe, Asia, and North America.

Cosmos Holdings (Nasdaq: COSM) announced significant milestones in a shareholder letter dated March 23, 2022. The company successfully uplisted to the Nasdaq and raised $6 million. Their 2021 initiatives included launching new nutraceutical products and establishing distribution deals on Amazon UK and Alibaba's Tmall. Cosmos aims for a 15-20% revenue growth in 2022, targeting $65 million while improving gross margins to 18%. The global nutraceutical market is projected to grow from $352.9 billion in 2021 to $658.1 billion by 2028, presenting a robust landscape for the company.

Cosmos Holdings, Inc. (Nasdaq: COSM) has successfully closed a private placement offering, raising approximately $6 million by selling 6,000 shares of Series A Convertible Preferred Stock and 2,000,000 warrants. Each preferred share was priced at $1,000, reflecting its stated value. The new capital will enhance the company's financial position, while the holders of preferred stock have rights to convert their shares into common stock at an attractive conversion price. The warrants, priced at $3.30 per share, are exercisable over the next five and a half years.

Cosmos Holdings (COSM) announced a private placement to raise approximately $6 million through the sale of 6,000 shares of Series A Convertible Preferred Stock and warrants for 2 million common shares. Each preferred share is priced at $1,000. The offering coincides with Cosmos's successful listing on the Nasdaq Capital Market. CEO Greg Siokas emphasized the company's scalable business model and plans for global expansion of its nutraceuticals and third-party pharmaceuticals. The company converted over $11 million in debt to equity, strengthening its balance sheet for future growth.